Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT01772810Phase 1Unknown

Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI

Role: lead

NCT02695472Phase 2Unknown

Study of NSI-189 for Major Depressive Disorder

Role: lead

NCT02724735Unknown

A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder

Role: lead

NCT01348451Phase 1Unknown

Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

Role: lead

NCT01730716Phase 2Unknown

Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

Role: lead

NCT01520649Phase 1Completed

Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects

Role: lead

NCT01310881Phase 1Completed

Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189

Role: lead

All 7 trials loaded